SG Americas Securities LLC Acquires 49,981 Shares of Viridian Therapeutics, Inc. $VRDN

SG Americas Securities LLC lifted its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 411.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,118 shares of the company’s stock after purchasing an additional 49,981 shares during the quarter. SG Americas Securities LLC’s holdings in Viridian Therapeutics were worth $1,341,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of VRDN. Simplify Asset Management Inc. bought a new stake in Viridian Therapeutics during the 3rd quarter worth approximately $1,079,000. Rice Hall James & Associates LLC lifted its stake in Viridian Therapeutics by 65.2% in the third quarter. Rice Hall James & Associates LLC now owns 851,663 shares of the company’s stock valued at $18,379,000 after buying an additional 336,040 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Viridian Therapeutics by 332.1% in the third quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock valued at $42,000 after buying an additional 1,491 shares during the period. Hudson Bay Capital Management LP bought a new stake in shares of Viridian Therapeutics during the second quarter worth $1,671,000. Finally, Tower Research Capital LLC TRC increased its position in shares of Viridian Therapeutics by 867.0% during the second quarter. Tower Research Capital LLC TRC now owns 16,227 shares of the company’s stock worth $227,000 after acquiring an additional 14,549 shares in the last quarter.

Insider Activity at Viridian Therapeutics

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 2,272 shares of the company’s stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $31.16, for a total transaction of $70,795.52. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Fairmount Funds Management Llc purchased 454,545 shares of the business’s stock in a transaction on Thursday, October 23rd. The stock was purchased at an average price of $22.00 per share, with a total value of $9,999,990.00. Following the purchase, the director owned 3,914,458 shares of the company’s stock, valued at approximately $86,118,076. The trade was a 13.14% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 1.58% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on VRDN. Royal Bank Of Canada boosted their price objective on shares of Viridian Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Wall Street Zen raised Viridian Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. William Blair initiated coverage on Viridian Therapeutics in a report on Wednesday, December 3rd. They issued an “outperform” rating on the stock. Needham & Company LLC increased their price objective on Viridian Therapeutics from $34.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, December 23rd. Finally, BTIG Research reissued a “buy” rating and issued a $61.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, November 4th. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.31.

Viridian Therapeutics Price Performance

NASDAQ:VRDN opened at $33.26 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 11.28 and a current ratio of 11.28. The stock’s 50-day simple moving average is $31.28 and its 200 day simple moving average is $23.54. The company has a market cap of $3.17 billion, a P/E ratio of -11.01 and a beta of 0.90. Viridian Therapeutics, Inc. has a 52-week low of $9.90 and a 52-week high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.48. The firm had revenue of $70.57 million during the quarter, compared to analysts’ expectations of $16.21 million. Viridian Therapeutics had a negative return on equity of 78.50% and a negative net margin of 426.58%.The firm’s revenue for the quarter was up 81993.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.